Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the high response rates of targeted therapy and the durability of responses with immunotherapy. However, the first clinical trial testing the combination of the BRAF inhibitor vemurafenib and the CTLA-4...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Transl Med
Main Authors: Hu-Lieskovan, Siwen, Mok, Stephen, Moreno, Blanca Homet, Tsoi, Jennifer, Faja, Lidia Robert, Goedert, Lucas, Pinheiro, Elaine M., Koya, Richard C., Graeber, Thomas, Comin-Anduix, Begoña, Ribas, Antoni
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4765379/
https://ncbi.nlm.nih.gov/pubmed/25787767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aaa4691
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki